What is the most recent earnings date for GEHC stock?
GE HEALTHCARE TECHNOLOGY (GEHC) last reported earnings on 2/4/2026.
NASDAQ:GEHC • US36266G1076
Past quarterly earnings results for GE HEALTHCARE TECHNOLOGY (GEHC), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 1.44 | 1.43 | 0.96% | -0.69% | 5.698B | 5.723B | -0.44% | 7.13% |
| Q3 2025 | 1.07 | 1.07 | -0.16% | -6.14% | 5.143B | 5.182B | -0.75% | 5.76% |
| Q2 2025 | 1.06 | 0.94 | 13.24% | 6.00% | 5.007B | 5.062B | -1.09% | 3.47% |
| Q1 2025 | 1.01 | 0.93 | 8.42% | 12.22% | 4.777B | 4.757B | 0.42% | 2.73% |
| Q4 2024 | 1.45 | 1.29 | 12.49% | 22.88% | 5.319B | 5.437B | -2.17% | 2.17% |
| Q3 2024 | 1.14 | 1.07 | 6.17% | 15.15% | 4.863B | 4.966B | -2.07% | 0.85% |
| Q2 2024 | 1.00 | 1.00 | 0.18% | 8.70% | 4.839B | 4.97B | -2.64% | 0.46% |
| Q1 2024 | 0.90 | 0.92 | -2.68% | 5.88% | 4.65B | 4.897B | -5.04% | -1.21% |
| Q4 2023 | 1.18 | 1.09 | 8.08% | -9.92% | 5.206B | 5.193B | 0.25% | 5.43% |
| Q3 2023 | 0.99 | 0.91 | 8.23% | - | 4.822B | 4.901B | -1.61% | 5.38% |
| Q2 2023 | 0.92 | 0.89 | 3.67% | - | 4.817B | 4.89B | -1.49% | -45.43% |
| Q1 2023 | 0.85 | 0.81 | 5.15% | - | 4.707B | 4.727B | -0.42% | - |
| Q4 2022 | 1.31 | - | - | 4.938B | - | 7.61% | ||
| Q3 2022 | - | - | 4.576B | - | 6.32% | |||
| Q2 2022 | - | - | 8.827B | - | 1.55% | |||
| Q4 2021 | - | - | 4.589B | - | - | |||
| Q3 2021 | - | - | 4.304B | - | - | |||
| Q2 2021 | - | - | 8.692B | - | - |
Notes
GE HEALTHCARE TECHNOLOGY (GEHC) last reported earnings on 2/4/2026.
GE HEALTHCARE TECHNOLOGY (GEHC) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, GE HEALTHCARE TECHNOLOGY (GEHC) has beaten EPS estimates in 3 out of 4 releases.